213 results about "Therapy eye" patented technology

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

A medical device for office-based / operating room bleb forming minimally invasive glaucoma surgeries. The medical device includes a proximal segment for grasping by a user, a distal segment that includes a piercing member coupled to and extending from the distal segment, wherein the piercing member is configured to contain and deliver an ocular implant into an eye tissue layer to obtain a channel, wherein the proximal segment and the distal segment being configured to couple to each other at a pivot point between an unlocked configuration and a locked configuration, and wherein in the unlocked configuration, the proximal segment and the distal segment are rotatable relative to each other about a rotation axis at the pivot point.

An ophthalmic lens configured to correct and / or treat at least one condition of the eye (e.g., presbyopia, myopia, hyperopia, astigmatism, binocular vision disorders, night vision image quality, and / or visual fatigue syndrome) comprising: a base power profile; and at least one pulse selected to modify the base power profile.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The invention provides methods of treating an eye disorder and compositions for use therein, the methods comprising applying a crosslinkable liquid composition onto an anterior corneal surface of said eye using a mold; crosslinking the crosslinkable liquid composition on the anterior corneal surface of the eye, thereby obtaining a crosslinked composition on the anterior corneal surface of the eye; and correcting the curvature of the crosslinked composition.

Transcorneal and fiberoptic laser delivery systems and methods for the treatment of eye diseases wherein energy is delivered by wavelengths transparent to the cornea to effect target tissues in the eye for the control of intraocular pressure in diseases such as glaucoma by delivery systems both external to and within ocular tissues. External delivery may be affected under gonioscopic control. Internal delivery may be controlled endoscopically or fiberoptically, both systems utilizing femtosecond laser energy to excise ocular tissue. The femtosecond light energy is delivered to the target tissues to be treated to effect precisely controlled photodisruption to enable portals for the outflow of aqueous fluid in the case of glaucoma in a manner which minimizes target tissue healing responses, inflammation and scarring.

A system for treating an eye comprising a tissue stored within a lumen of an elongated cannula, the tissue comprises scleral, amniotic membrane, or acellular biomatrix tissue and having an elongated form factor. Related devices, systems, and methods are provided.

Described herein are devices used to treat high intraocular pressure and glaucoma. An example device includes a plate comprising a first surface opposite a second surface. The first surface includes a series of fluid channels. The device also includes a first coating on the first surface and a second coating on the second surface. The device is configured to lower intraocular pressure by draining aqueous humor from an anterior chamber to subconjunctival space of a patient's eye.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

A system for treating a media opacity in a vitreous media of an eye includes a visualization module adapted to provide visualization data of a portion of the eye via one or more viewing beams. The system includes a laser module adapted to selectively generate a treatment beam directed towards the media opacity in order to disrupt the media opacity. The laser module and the visualization module have a shared aperture for guiding the treatment beam and the one or more viewing beams towards the eye, the shared aperture being centered about a central axis. A controller is configured to acquire one or more defining parameters of the media opacity and determine when the media opacity is with a predefined target zone of a real-time viewing window. The media opacity is treated with the treatment beam when the media opacity is within the predefined target zone.

A light based system for treating an eye includes a mask that is configured for positioning on the eye and a light source that is configured to deliver therapeutic light. The mask has an inner surface that is positionable against the eye and an outer surface that is opposite the inner surface. The mask is optically opaque to prevent transmission of light through the mask and the mask includes at least one transparent opening that allows transmission of light through the mask to target tissue of the eye posterior the transparent opening. The light source is positioned relative to the mask so that the delivered therapeutic light irradiates at least a portion of the mask and the transparent opening. Therapeutic light traverses through the transparent opening to the target tissue positioned posterior the transparent opening.

Systems, devices and methods are provided that provide assistance in selecting appropriate interventions for treatment of disease and injury to the eye. Systems of the inventive concept provide cloud-based processing and storage of clinical and patient-specific data, which can provide treatment recommendations and projected outcomes to a practitioner using a local device. Systems, devices, and methods can generate interactive physiomechanical models of the eye of a specified individual, which are derived measurements of mechanical properties of structures of the eye. The physiomechanical model is interactive, and can be used to emulate the effects of one or more medical interventions in the eye in order to implement an optimized treatment plan for the individual.

This invention relates to the use of recombinant type III humanized collagen and compositions comprising thereof in the ocular field. The invention provides the use of recombinant type III humanized collagen in the preparation of products for the prevention and / or treatment of ocular inflammation, and compositions comprising recombinant type III humanized collagen, and the use of these compositions in the preparation of products for the prevention and / or treatment of ocular inflammation and / or dry eye. Recombinant type III humanized collagen and compositions comprising thereof can significantly promote the renewal and repair of corneal epithelial cells, while inhibiting the release of inflammatory mediators, strengthening the ocular tissue barrier, enhancing tear film stability, and relieving ocular inflammation and dry eye.

The present application relates to an ophthalmic preparation and use thereof. Specifically, the present application relates to an ophthalmic preparation of pilocarpine and use thereof for treating eye diseases. The ophthalmic preparation of pilocarpine provided by the present application has the beneficial effects of good stability and less eye irritation.

Provided herein are methods and compositions for improving the visual function of an eye having an ocular disorder. Provided herein are methods of treating an ocular lesion of an eye of an individual, the method comprising: (a) administering a first composition comprising a Fas inhibitor. In some embodiments, the method further comprises (b) administering a second composition comprising a Fas inhibitor, where the second composition is administered for about 10 weeks or more after the first composition is administered.

The present invention concerns an ophthalmic composition comprising:hyaluronic acid, or one of its salts, advantageously of a molecular weight comprised between 100 and 800 kDa;an oligosaccharide, advantageously a diholoside, more advantageously trehalose; andresveratrol;and its use for treating ocular diseases such as DED.

An implant device for an eye disease to be inserted into an eyeball may include: a tube having one end to be inserted into an anterior chamber of the eyeball, the tube comprising a hollow portion through which aqueous humor is drained; and a ripcord inserted into the hollow portion of the tube to control an amount of aqueous humor drainage through the tube. In the implant device, an inner diameter of the tube and a diameter of the ripcord are determined so that pressure formed in the anterior chamber of the eyeball when the tube is inserted into the anterior chamber of the eyeball is within a preset pressure range. The pressure formed in an anterior chamber to an optimal range through an appropriate combination of the tube and the ripcord inserted into the tube.

A system for treating an eye comprising a tissue stored within a lumen of an elongated cannula, the tissue comprises scleral. amniotic membrane, or acellular biomatrix tissue and having an elongated form factor. Related devices, systems, and methods are provided.

Pharmaceutical compositions, methods for treating various issues of the eyes, and methods of preparing such compositions are described. These pharmaceutical compositions may be for treating glaucoma, in preparation of eye surgery, during eye surgery, various post-op care (e.g., after cataract surgery, laser eye surgery, and the like), for treating dry eyes, and / or for promoting eyelash growth. These pharmaceutical compositions may comprise such active ingredients (APIs) as: timolol, latanoprost, brimonidine tartrate, dorzolamide, moxifloxacin HCl, dexamethasone PO4, phenylephrine HCl, lidocaine HCl, ketorolac tromethamine, bromfenac, prednisolone PO4, gatifloxacin, amniotic cytokine extract (ACE), prostaglandin E2 (PGE2), and combinations thereof.

In certain embodiments, an ophthalmic laser surgical system for treating a target tissue in an eye includes a target detection system and a laser device. The target tissue has an optical breakdown threshold. The target detection system directs detection beams along a detection beam path towards the target tissue in a vitreous of the eye, and determines a location of the target tissue within the vitreous. The laser device includes a femtosecond laser that generates subthreshold laser pulses that have a pulse energy below the optical breakdown threshold of the tissue. The laser device directs a laser beam comprising the subthreshold laser pulses along a laser beam path towards the target tissue.

The application discloses a kind of laser treatment devices for ophthalmology, and it relates to the technical field of medical apparatus and instruments.The application includes eyeshade shell, massage column is slidably installed in eyeshade shell, camber surface drive ring is rotatably installed in eyeshade shell, sliding sheet is fixedly installed on massage column, hemispherical block is fixedly installed on sliding sheet, laser light source beam splitter is fixedly installed in eyeshade shell, a plurality of laser needle columns are fixedly installed at the output end of laser light source beam splitter, first light guide groove is provided in massage column, threaded groove is provided at the front end of eyeshade shell, liquid storage shell, liquid medicine atomization nozzle and liquid distribution shell are also fixedly installed in eyeshade shell, liquid inlet pipe is fixedly installed at the top end of liquid storage shell, liquid distribution pipe is fixedly installed and communicated on liquid distribution shell, atomization liquid pipe is fixedly installed and communicated on liquid medicine atomization nozzle, ultrasonic atomization sheet is fixedly installed in liquid medicine atomization nozzle, eye peripheral acupoints can be stimulated by laser acupuncture, the massage effect of massage column is combined, drug mist absorption is promoted, and the effect of treating ophthalmic diseases is achieved.

System and method for using in treatment of an opacity within an eye are presented, the system comprising an input utility configured to receive input data comprising image data of the eye being indicative of a convergence spot of first and second aiming beams entering the eye and converging at location of an opacity within the eye, and of first and second spots formed on the retina by respectively the first and second aiming beams; a processing utility configured to process the input data, the processing comprises processing the image data and determining an inter-spot distance between the first and second spots formed on the retina, and utilizing the inter-spot distance and a model of the eye and determining a first distance between the opacity and the retina and a second distance between the opacity and the crystalline lens of the eye; and an output utility configured and operable to generate output data indicative of opacity treatment recommendation based on the first and second distances.

Intraocular implants may include a corticosteroid and a biodegradable polymer associated with the corticosteroid to facilitate the release of the corticosteroid into an eye for a period of time. In some embodiments, ocular conditions, such as diabetic macular edema can be treated through administration of an intraocular implant including a corticosteroid and a biodegradable polymer associated with the corticosteroid to the eye of a human at a frequency of about once every six months to about once a year.

The present disclosure relates to intraocular implants for treating a condition of the eye, wherein the implant is configured to deliver a drug to the eye. The present disclosure also relates to methods of treating a condition of the eye by delivering a drug from intraocular implants to the posterior chamber (e.g., sulcus), iridocorneal angle, sclera, cornea, limbus, and vitreous.

The invention relates to a method for providing control data for an ophthalmic laser (12) of a treatment device (10), wherein the method comprises the following steps performed by a control unit (18): receiving anatomical data relating to the anatomy of a cornea (16) of an eye to be treated; determining the position of the corneal nerve plexus (24) in the cornea (16) based on the anatomical data of the cornea (16) to be treated; determining the depth distribution of the corneal nerve plexus (24) in the cornea (16); receiving cutting instructions for performing a cut (26) in the cornea (16) by the ophthalmic laser (12) of the treatment device (10); Determining a target depth (28) for the laser (12) to perform the cut (26) based on the cut specifications and the depth distribution of the corneal nerve plexus (24) according to a specified cut depth specification;and generating control data for controlling the ophthalmic laser (12) to perform the cut (26) in the cornea (16).;

The device of the present invention allows for a method of treating a patient exhibiting proptosis of eye tissue by treating inflamed tissue behind the eye or treating the thyroid directly or treating a reflexology zone to reduce pressure and inflammation of the eye tissue using pressure pulses or shock waves. The treatment method for bulging eyes has the steps of placing an applicator head of an acoustic shock wave or pressure pulse generator or source on or near an eye or eyelid region, temple, thyroid or reflexology zone; coupling the applicator head directly or indirectly to an exposed surface of the region being treated; and activating the generator or source to emit pressure pulses or acoustic shock waves to the eye or eyelid region, temple, thyroid or reflexology zone to treat the eye tissue exhibiting high pressure and inflammation to reduce the pressure and inflammation.

The present invention relates to hydrogels, methods of making them, their use in the treatment of eye disorders and as bandage contact lenses. The present invention also provides modified poly-ε-lysine polymers and methods of making them.